Benefits of Ascorbic Acid in Association with Low-Dose Benznidazole in Treatment of Chagas Disease | Zendy

Maiara Voltarelli Providello | Zendy; Zumira A. Carneiro | Zendy; Gisele Bulhões Portapilla | Zendy; Gabriel Tavares do Vale | Zendy; Ricardo Souza Camargo | Zendy; Carlos R. Tirapelli | Zendy; Sérgio de Albuquerque | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Benefits of Ascorbic Acid in Association with Low-Dose Benznidazole in Treatment of Chagas Disease

Author(s) -

Maiara Voltarelli Providello,

Zumira A. Carneiro,

Gisele Bulhões Portapilla,

Gabriel Tavares do Vale,

Ricardo Souza Camargo,

Carlos R. Tirapelli,

Sérgio de Albuquerque

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00514-18

Subject(s) - benznidazole , pharmacology , parasitemia , ascorbic acid , oxidative stress , chagas disease , nifurtimox , trypanosoma cruzi , reactive oxygen species , lipid peroxidation , glutathione , in vivo , biology , medicine , biochemistry , immunology , enzyme , parasite hosting , food science , world wide web , computer science , microbiology and biotechnology , malaria , plasmodium falciparum

The acute phase of Chagas disease (CD) is characterized by high parasitic proliferation and intense inflammation, exacerbating the generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS). These reactive molecules are also increased by the metabolism of the nitroheterocyclic compounds benznidazole (BZ) and nifurtimox, the only drugs available for the treatment of CD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research